Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to declare certain listed food color additives unsafe and foods containing them adulterated. Beginning December 31, 2025, Citrus Red No. 2 and Orange B are deemed unsafe.
Precautionary health action versus procedural scientific review
Relative to its intended legislative type, this bill is a concise, direct substantive statutory change that clearly names affected substances and sets effective dates, and it integrates with specific FD&C Act provisions.
The bill amends the Federal Food, Drug, and Cosmetic Act to declare certain listed food color additives unsafe and foods containing them adulterated.
Beginning December 31, 2025, Citrus Red No. 2 and Orange B are deemed unsafe.
Beginning December 31, 2026, Red No. 40, Yellow Nos. 5 and 6, Green No. 3, Blue Nos. 1 and 2, and substantially similar additives are deemed unsafe.
Targeted regulatory ban with high economic impact and weak compromise features; short text but substantial resistance expected.
Relative to its intended legislative type, this bill is a concise, direct substantive statutory change that clearly names affected substances and sets effective dates, and it integrates with specific FD&C Act provisions. However, it provides limited implementation detail, no fiscal or resourcing acknowledgements, and leaves ambiguous terms (e.g., 'substantially similar') undefined.
Precautionary health action versus procedural scientific review
These are examples from the analysis, not a ranked list of the most-affected groups.
Precautionary health action versus procedural scientific review
Likely broadly supportive, viewing the bill as a precautionary public-health measure to reduce exposure to synthetic food dyes.
Would emphasize potential benefits for children's health, environmental concerns, and encouraging natural alternatives, while urging support for affected small businesses.
Cautiously open to the bill's intent if backed by evidence and orderly implementation.
Concerned about bypassing normal FDA certification processes and the lack of implementation detail, so would seek impact analysis and phased enforcement.
Likely opposed as regulatory overreach that undermines FDA authority and imposes costs on businesses and consumers.
Emphasizes procedural concerns, economic burdens, and preserving agency expertise over congressional overrides.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted regulatory ban with high economic impact and weak compromise features; short text but substantial resistance expected.
The bill has not accumulated any surfaced votes yet.
Precautionary health action versus procedural scientific review
Targeted regulatory ban with high economic impact and weak compromise features; short text but substantial resistance expected.
Relative to its intended legislative type, this bill is a concise, direct substantive statutory change that clearly names affected substances and sets effective dates, and it integrates with specific FD&C Act provisions…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.